JPS5865215A - 医薬組成物 - Google Patents
医薬組成物Info
- Publication number
- JPS5865215A JPS5865215A JP57153791A JP15379182A JPS5865215A JP S5865215 A JPS5865215 A JP S5865215A JP 57153791 A JP57153791 A JP 57153791A JP 15379182 A JP15379182 A JP 15379182A JP S5865215 A JPS5865215 A JP S5865215A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- indomethacin
- ranitidine
- ibuprofen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title description 9
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 229960000905 indomethacin Drugs 0.000 claims description 10
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 8
- 229960001680 ibuprofen Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 229960000620 ranitidine Drugs 0.000 claims description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229950006236 fenclofenac Drugs 0.000 claims description 2
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 claims description 2
- 229960004369 flufenamic acid Drugs 0.000 claims description 2
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 2
- 150000003840 hydrochlorides Chemical class 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001017 tolmetin Drugs 0.000 claims description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims 2
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 claims 1
- 229960001395 fenbufen Drugs 0.000 claims 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 claims 1
- 229960000489 feprazone Drugs 0.000 claims 1
- 229960003464 mefenamic acid Drugs 0.000 claims 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 1
- 229960000894 sulindac Drugs 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 8
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 8
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- -1 compression aids Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8126786 | 1981-09-04 | ||
| GB26786 | 1981-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS5865215A true JPS5865215A (ja) | 1983-04-18 |
Family
ID=10524316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57153791A Pending JPS5865215A (ja) | 1981-09-04 | 1982-09-03 | 医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| JP (1) | JPS5865215A (fr) |
| AU (1) | AU564018B2 (fr) |
| BE (1) | BE894285A (fr) |
| CH (1) | CH652304A5 (fr) |
| DE (1) | DE3232830C2 (fr) |
| FR (1) | FR2512342B1 (fr) |
| HK (1) | HK91387A (fr) |
| IE (1) | IE54149B1 (fr) |
| IT (1) | IT1208432B (fr) |
| KE (1) | KE3739A (fr) |
| MY (1) | MY8700560A (fr) |
| NL (1) | NL193821C (fr) |
| SE (1) | SE8205034L (fr) |
| SG (1) | SG59387G (fr) |
| ZA (1) | ZA826477B (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01197444A (ja) * | 1986-03-04 | 1989-08-09 | Bristol Myers Co | 非ステロイド系抗炎症組成物によって生じる消化管損傷に対するβ−アドレナリン作用薬とある種のヒスタミンＨ↓１−および／またはＨ↓２−受容体遮断薬との組合せの効果 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
| FR2636532B1 (fr) * | 1988-09-20 | 1993-11-19 | Glaxo Group Ltd | Compositions pharmaceutiques |
| JP2002542205A (ja) * | 1999-04-19 | 2002-12-10 | リチャード ワイスバート、 | 貯蔵ヒト免疫グロブリンおよび制酸剤の経口投与による成人リウマチ様関節炎の処置 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2360306A1 (fr) * | 1976-08-03 | 1978-03-03 | Huguet Georgette | Nouveaux medicaments antalgiques, antiseptiques et anti-inflammatoires |
| GB1565966A (en) * | 1976-08-04 | 1980-04-23 | Allen & Hanburys Ltd | Aminoalkyl furan derivatives |
-
1982
- 1982-09-02 BE BE0/208936A patent/BE894285A/fr not_active IP Right Cessation
- 1982-09-03 SE SE8205034A patent/SE8205034L/xx unknown
- 1982-09-03 IE IE2152/82A patent/IE54149B1/en not_active IP Right Cessation
- 1982-09-03 IT IT8249071A patent/IT1208432B/it active
- 1982-09-03 JP JP57153791A patent/JPS5865215A/ja active Pending
- 1982-09-03 DE DE3232830A patent/DE3232830C2/de not_active Expired - Lifetime
- 1982-09-03 CH CH5245/82A patent/CH652304A5/fr not_active IP Right Cessation
- 1982-09-03 AU AU87997/82A patent/AU564018B2/en not_active Expired
- 1982-09-03 ZA ZA826477A patent/ZA826477B/xx unknown
- 1982-09-03 NL NL8203457A patent/NL193821C/nl not_active IP Right Cessation
- 1982-09-03 FR FR8215042A patent/FR2512342B1/fr not_active Expired
-
1987
- 1987-07-10 KE KE3739A patent/KE3739A/xx unknown
- 1987-07-22 SG SG593/87A patent/SG59387G/en unknown
- 1987-12-03 HK HK913/87A patent/HK91387A/xx not_active IP Right Cessation
- 1987-12-30 MY MY560/87A patent/MY8700560A/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01197444A (ja) * | 1986-03-04 | 1989-08-09 | Bristol Myers Co | 非ステロイド系抗炎症組成物によって生じる消化管損傷に対するβ−アドレナリン作用薬とある種のヒスタミンＨ↓１−および／またはＨ↓２−受容体遮断薬との組合せの効果 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3232830C2 (de) | 1994-12-08 |
| AU8799782A (en) | 1983-03-10 |
| SE8205034L (sv) | 1983-03-05 |
| SG59387G (en) | 1987-10-23 |
| NL8203457A (nl) | 1983-04-05 |
| NL193821B (nl) | 2000-08-01 |
| KE3739A (en) | 1987-09-04 |
| FR2512342B1 (fr) | 1986-09-05 |
| IT8249071A0 (it) | 1982-09-03 |
| NL193821C (nl) | 2000-12-04 |
| BE894285A (fr) | 1983-03-02 |
| CH652304A5 (fr) | 1985-11-15 |
| AU564018B2 (en) | 1987-07-30 |
| MY8700560A (en) | 1987-12-31 |
| DE3232830A1 (de) | 1983-03-24 |
| SE8205034D0 (sv) | 1982-09-03 |
| IT1208432B (it) | 1989-06-12 |
| IE54149B1 (en) | 1989-07-05 |
| ZA826477B (en) | 1984-04-25 |
| HK91387A (en) | 1987-12-11 |
| FR2512342A1 (fr) | 1983-03-11 |
| IE822152L (en) | 1983-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5859060A (en) | Timed release tablet comprising naproxen and pseudoepherine | |
| GB2105193A (en) | Pharmaceutical compositions containing non-steroidal anti-inflammatory agents | |
| US4757060A (en) | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers | |
| US5037815A (en) | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers | |
| RU99107283A (ru) | Не содержащие лактозы, негигроскопичные и безводные фармацевтические препараты дескарбоэтоксилоратадина | |
| RU2007126652A (ru) | Композиции и способы стабилизации активных фармацевтических ингредиентов | |
| US5466436A (en) | Medicaments for treating inflammatory conditions or for analgesia | |
| KR870003778A (ko) | 신규 약제의 제조방법 | |
| JP3874793B2 (ja) | イブプロフェンおよびコデイン含有の改良された医薬処方 | |
| RU2005115883A (ru) | Композиции с контролируемым высвобождением | |
| JPH06502854A (ja) | 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用 | |
| HU186855B (en) | Process for producing galenic pharmaceutical compositions with controlled solving-out of active agents | |
| CZ270999A3 (cs) | Farmaceutické prostředky obsahující ibuprofen a domperidone pro ošetřování migrény | |
| JPS5865215A (ja) | 医薬組成物 | |
| US5260333A (en) | Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions | |
| US5998478A (en) | Timed release tablet comprising naproxen and pseudoephedrine | |
| GB2216413A (en) | Medicaments containing sufotidine | |
| JP2006001920A (ja) | 医薬製剤 | |
| JPS5855421A (ja) | 医薬組成物 | |
| EP0017169A1 (fr) | Combinaisons anti-inflammatoires avec un effet ulcérogène réduit | |
| RU2134579C1 (ru) | Лекарственные средства для лечения воспалительных состояний или для анальгезии | |
| US6099860A (en) | Controlled release oral preparation with naproxen sodium and pseudoephedrine | |
| EP1107740A1 (fr) | Comprime a liberation lente comprenant du naproxene et de la pseudoephedrine | |
| WO1994009767A1 (fr) | Nouvelle utilisation de compositions pharmaceutiques | |
| JP2020105108A (ja) | 糖衣錠 |